Surgery in haemophilic patients with inhibitor: 20 years of experience
- 22 September 2004
- journal article
- Published by Wiley in Haemophilia
- Vol. 10 (s2) , 30-40
Abstract
Summary. Surgery in haemophilic patients with inhibitor against factor (F)VIII or FIX is high risk. Surgery may be performed with the administration of sufficiently high dose of FVIII in patients with low‐response inhibitor or who, despite having a high response, present a low inhibitor titre at the time of surgery. The use of high doses of FX is more complicated in patients with a low‐titre FIX inhibitor, as there is a high risk of anaphylactic reactions. In the case of patients with high‐titre inhibitors, several treatments have been proposed, such as porcine FVIII, recombinant FVIIa (rFVIIa), and activated prothrombin complex concentrate (APCC). We present our 20 years' experience in the treatment and subsequent management of haemophilic patients with inhibitor in surgery and evaluate the results obtained with the products available for haemostatic control in 64 surgical procedures. The efficacy we obtained with FVIII is good in 100% of the cases described; we had no haemorrhagic complication (HC) in the 18 procedures in which it was used (three major and 15 minor surgery). With APCC we obtained excellent results with only one HC in a synoviorthesis in the form of bleeding and haematomas out of 32 procedures. Good results were obtained with rFVIIa with few haemorrhagic episodes. Thus, in major surgery there was one HC out of three cases. In minor surgery, greater efficacy was observed using extremely large doses of rFVIIa (≥ 120 mg kg−1 2h−1) because of the shorter half‐life of this factor in this type of patients.Keywords
This publication has 35 references indexed in Scilit:
- Immune tolerance treatment in haemophilia patients with inhibitors: the Spanish RegistryHaemophilia, 2001
- Continuous infusion of recombinant activated factor VII during caesarean section delivery in a patient with congenital factor VII deficiencyHaemophilia, 2000
- Use of prothrombin complex concentrates and activated prothrombin complex concentrates as prophylactic therapy in haemophilia patients with inhibitorsHaemophilia, 1999
- Induction of Immune Tolerance in Haemophilia A Inhibitor Patients by the ‘Bonn Protocol’: Predictive Parameter for Therapy Duration and OutcomeVox Sanguinis, 1999
- Analysis of the North American Immune Tolerance Registry (NAITR) 1993–1997: Current Practice ImplicationsVox Sanguinis, 1999
- Optimal care of inhibitor patients during surgeryEuropean Journal of Haematology, 1998
- Immunoadsorption for removal of inhibitors: update on treatments in Malmö–Lund between 1980 and 1995Haemophilia, 1998
- Prevalence of factor IX inhibitors among patients with haemophilia B: results of a large‐scale North American surveyHaemophilia, 1996
- Hepatitis C antibody profile and viraemia prevalence in adults with severe haemophiliaBritish Journal of Haematology, 1991
- Induction of immune tolerance to factor VIII in hemophiliacs with inhibitorsJAMA, 1988